BiVictriX Therapeutics plc (BVX) Ord GBP0.01
BiVictriX Therapeutics plc is a United Kingdom-based drug discovery and development company focused on developing cancer therapeutics. The Company’s lead program, BVX001, is a Bi-Cygni antibody drug conjugate (ADC) designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with acute myeloid leukemia (AML), and in subpopulations of cancer cells from patients with other hematological cancers. The Company generates a pipeline of Bi-Cygni ADC therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints on tumor cells, which are largely absent from healthy cells. It has established a library of cancer-specific Bi-Cygni fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilizes these Bi-Cygni fingerprints, together with the Company’s ADC therapeutic design, to develop therapeutics to target cancers.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.